Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, et al.
Cell Metabolism (2016) Vol. 24, Iss. 1, pp. 51-62
Open Access | Times Cited: 216

Showing 51-75 of 216 citing articles:

Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity
Carmelo Quarta, Christoffer Clemmensen, Zhimeng Zhu, et al.
Cell Metabolism (2017) Vol. 26, Iss. 4, pp. 620-632.e6
Open Access | Times Cited: 79
Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction
John R. Ussher, Jonathan E. Campbell, Erin E. Mulvihill, et al.
Cell Metabolism (2017) Vol. 27, Iss. 2, pp. 450-460.e6
Open Access | Times Cited: 76
Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes
Jia Ying Cheang, Peter M. Moyle
ChemMedChem (2018) Vol. 13, Iss. 7, pp. 662-671
Closed Access | Times Cited: 71
The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice
Jacqueline L. Beaudry, Kiran Deep Kaur, Elodie M. Varin, et al.
Molecular Metabolism (2019) Vol. 22, pp. 37-48
Open Access | Times Cited: 68
Free Fatty Acid Receptors in Enteroendocrine Cells
Van B. Lu, Fiona M. Gribble, Frank Reimann
Endocrinology (2018) Vol. 159, Iss. 7, pp. 2826-2835
Open Access | Times Cited: 64
<p>Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications</p>
Min Gong, Song Wen, Thiquynhnga Nguyen, et al.
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 943-962
Open Access | Times Cited: 64
Obesity medications in development
Candida J. Rebello, Frank L. Greenway
Expert Opinion on Investigational Drugs (2019) Vol. 29, Iss. 1, pp. 63-71
Open Access | Times Cited: 58
Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Nathalia Romanelli Vicente Dragano, Johan Fernø, Carlos Diéguez, et al.
Neuroscience (2020) Vol. 437, pp. 215-239
Closed Access | Times Cited: 58
<p>Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential</p>
Marie Bastin, Fabrizio Andréelli
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 1973-1985
Open Access | Times Cited: 56
Glucagon's Metabolic Action in Health and Disease
Anja Zeigerer, Revathi Sekar, Maximilian Kleinert, et al.
Comprehensive physiology (2021), pp. 1759-1783
Open Access | Times Cited: 54
Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application
Mona C. Löffler, Matthias J. Betz, Denis P. Blondin, et al.
Molecular Metabolism (2021) Vol. 51, pp. 101237-101237
Open Access | Times Cited: 53
Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study
Nicholas A. Di Prospero, Jaqueline Yee, Mary Ellen Frustaci, et al.
Clinical Obesity (2021) Vol. 11, Iss. 2
Closed Access | Times Cited: 50
Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics
Anita Kabahizi, Briana Wallace, Linh Lieu, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 600-624
Open Access | Times Cited: 43
Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease
Julie Massart, Karima Begriche, Anne Corlu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1062-1062
Open Access | Times Cited: 30
Novel sulfonamide derivatives as multitarget antidiabetic agents: design, synthesis, and biological evaluation
Mohammed Salah Ayoup, Nourhan Khaled, Hamida Abdel‐Hamid, et al.
RSC Advances (2024) Vol. 14, Iss. 11, pp. 7664-7675
Open Access | Times Cited: 7
EJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity?
Miguel López
European Journal of Endocrinology (2017) Vol. 176, Iss. 5, pp. R235-R246
Open Access | Times Cited: 61
SF1-Specific AMPKα1 Deletion Protects Against Diet-Induced Obesity
Patricia Seoane‐Collazo, Juan Roa, Eva Rial‐Pensado, et al.
Diabetes (2018) Vol. 67, Iss. 11, pp. 2213-2226
Open Access | Times Cited: 58
Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?
Miguel López, Manuel Tena‐Sempere
Pharmacology & Therapeutics (2017) Vol. 178, pp. 109-122
Open Access | Times Cited: 57
Glucagon Control on Food Intake and Energy Balance
Omar Al–Massadi, Johan Fernø, Carlos Diéguez, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 16, pp. 3905-3905
Open Access | Times Cited: 54
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Emily Sun, Alyce M. Martin, Richard L. Young, et al.
Frontiers in Endocrinology (2019) Vol. 9
Open Access | Times Cited: 51
Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status
Maushmi S. Kumar
Frontiers in Nutrition (2019) Vol. 6
Open Access | Times Cited: 51
Problem or solution: The strange story of glucagon
Rebecca Scott, Stephen R. Bloom
Peptides (2018) Vol. 100, pp. 36-41
Open Access | Times Cited: 50
Predicting Meridian in Chinese traditional medicine using machine learning approaches
Yinyin Wang, Mohieddin Jafari, Yun Tang, et al.
PLoS Computational Biology (2019) Vol. 15, Iss. 11, pp. e1007249-e1007249
Open Access | Times Cited: 50
Pharmacotherapy for Patients with Obesity
Kishore M. Gadde, John W. Apolzan, Hans‐Rudolf Berthoud
Clinical Chemistry (2017) Vol. 64, Iss. 1, pp. 118-129
Open Access | Times Cited: 49
Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors
Elita Yuliantie, Sanaz Darbalaei, Antao Dai, et al.
Biochemical Pharmacology (2020) Vol. 177, pp. 114001-114001
Closed Access | Times Cited: 49

Scroll to top